Outset Medical Appoints Steve Williamson as Chief Commercial Officer
Outset Medical, Inc. (Nasdaq: OM) has appointed Steve Williamson as Chief Commercial Officer to lead its commercial and service organizations, enhancing adoption of the Tablo Hemodialysis System. Under Williamson's leadership, the company experiences meaningful growth in health systems and received FDA clearance for home use. With over two decades in the medical technology field, including significant revenue growth at BD, Williamson aims to reduce dialysis costs and complexity, improving patient experiences.
- Appointment of Steve Williamson as CCO expected to drive growth in Tablo adoption.
- FDA clearance granted for home use of Tablo enhances market potential.
- Concerns about continuity or transition challenges with new leadership.
SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of Steve Williamson as Chief Commercial Officer. In this role, Mr. Williamson will lead Outset’s commercial and service organizations as adoption of the Tablo® Hemodialysis System continues to spread rapidly across the full spectrum of dialysis care, from hospitals to home.
“This year we have driven meaningful penetration within top regional and national health systems, and received FDA clearance for home,” said Leslie Trigg, President and Chief Executive Officer. “As we rapidly scale our organization to meet demand, Steve’s customer-centric, agile approach, combined with his ability to build high performance teams and culture will help fuel Outset for long-term growth.”
Mr. Williamson joins Outset Medical with over two decades of experience in the medical technology industry. Prior to joining Outset, he served as the Worldwide President for the approximately
“I am incredibly excited to join Outset and lead commercial efforts for Tablo, which provides a tremendous opportunity to reduce the cost and complexity of dialysis for providers while improving the experience of patients,” said Mr. Williamson. “The innovative platform and its ability to provide a solution for a drastically underserved patient population were significant factors in my decision to join Outset. I look forward to working with the team at Outset and supporting the company’s continued success, growth, and commitment to dialysis patients.”
About Outset Medical, Inc.
Outset is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. The Tablo Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers. Tablo serves as a single enterprise solution that can be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere and by anyone. The integration of water purification and on-demand dialysate production enables Tablo to serve as a dialysis clinic on wheels, with 2-way wireless data transmission and a proprietary data analytics platform powering a new holistic approach to dialysis care. Tablo is a registered trademark of Outset Medical, Inc.
